Will New Anti-eosinophilic Drugs Be Useful in Asthma Management?

Embed Cite Participate Recommend

Recently there has been great interest in the development of precision medicines that target a specific underlying disease mechanism so that responders will have a better therapeutic response and less adverse effects compared with the nonspecific therapies that are currently used. Peter Barnes is Professor of Thoracic Medicine and Head of Respiratory Medicine at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, London.

 

Publication

Image courtesy of interviewee

Log-in or Sign-up to Faculti
Currently viewing as guest. You have insight(s) remaining for this month.

Leave a Reply

Your email address will not be published.

Copyright © Faculti Media Limited 2023. All rights reserved.
Recommend Faculti to your librarian

Thousands of engaging insights, delivered at the world's leading institutions. 
Librarians welcome and value students, faculty and staff recommendations, and we aim to facilitate these suggestions in an impactful way.

error: